Solara Active Pharma Sciences Limited
NSE: SOLARA BSE: SOLARA
NSE
664.85
43.75 (7.04%)
Prev Close
621.1
Open Price
619.6
Volume
589,436
Today Low / High
618.7 / 679.85
52 WK Low / High
442.8 / 882.8
Range
632 - 698
BSE
663.85
41.35 (6.64%)
Prev Close
622.5
Open Price
622.5
Volume
45,940
Today Low / High
618.8 / 679.5
52 WK Low / High
441.1 / 885.95
Range
631 - 697
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 664.85 (target range: 632 - 698), reflecting a change of 43.75 (7.04395%). On the BSE, it is listed at 663.85 (target range: 631 - 697), showing a change of 41.35 (6.64257%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
11 Jul
619.60
7.30%
10 Jul
630.00
-1.41%
09 Jul
620.05
1.31%
08 Jul
631.00
-1.03%
07 Jul
635.00
-0.39%
04 Jul
633.25
0.56%
03 Jul
644.10
-1.16%
02 Jul
652.30
-0.81%
01 Jul
639.85
1.95%
30 Jun
620.05
2.74%
27 Jun
624.00
-1.01%
26 Jun
628.10
-1.16%
25 Jun
550.25
15.47%
24 Jun
539.70
1.91%
23 Jun
527.00
1.39%
20 Jun
529.00
0.18%
19 Jun
527.00
-0.52%
18 Jun
526.90
-0.41%
17 Jun
514.00
0.99%
16 Jun
510.00
-0.26%
Solara Active Pharma Sciences Limited Graph
Solara Active Pharma Sciences Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Solara Active Pharma Sciences Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 664.85, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 663.85 | 670.49 | 603.44 - 737.54 |
| 677.13 | 541.70 - 812.55 | ||
| 683.77 | 478.64 - 888.90 | ||
| Bearish Scenario | 663.85 | 657.21 | 591.49 - 722.93 |
| 650.57 | 520.46 - 780.69 | ||
| 643.93 | 450.75 - 837.11 |
Overview of Solara Active Pharma Sciences Limited
ISIN
INE624Z01016
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
215,459
Market Cap
32,014,522,050
Last Dividend
0
Official Website
IPO Date
2018-06-27
DCF Diff
1,164.86
DCF
-500
Financial Ratios Every Investor Needs
Stock Dividend of SOLARA
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2021-08-18 | August 18, 21 | 3 | 3 | 2021-08-20 | 2021-09-24 | |
| 2020-11-19 | November 19, 20 | 4 | 4 | 2020-11-20 | 2020-12-11 | |
| 2020-07-28 | July 28, 20 | 2 | 2 | 2020-07-29 | 2020-09-03 | 2020-05-07 |
| 2019-08-06 | August 06, 19 | 5 | 5 | 2019-08-07 | 2019-09-13 | 2019-05-16 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1,283.76 Cr | 626.41 Cr | 657.35 Cr | 0.5121 | 0.00 Cr | 0.00 Cr | 445.66 Cr | 0.54 Cr | 0.14 | 206.28 Cr | 0.0004 |
| 2024-03-31 | 1,274.10 Cr | 838.51 Cr | 435.59 Cr | 0.3419 | 0.00 Cr | 24.33 Cr | -198.08 Cr | -567.39 Cr | -145.27 | -282.19 Cr | -0.4453 |
| 2023-03-31 | 1,443.81 Cr | 788.82 Cr | 654.99 Cr | 0.4537 | 46.16 Cr | 229.92 Cr | 27.59 Cr | -22.17 Cr | -6.16 | 152.36 Cr | -0.0154 |
| 2022-03-31 | 1,230.55 Cr | 697.79 Cr | 532.76 Cr | 0.4329 | 65.62 Cr | 31.03 Cr | -25.99 Cr | -58.15 Cr | -16.18 | 88.50 Cr | -0.0473 |
| 2021-03-31 | 1,575.73 Cr | 769.58 Cr | 806.15 Cr | 0.5116 | 64.35 Cr | 32.85 Cr | 284.60 Cr | 221.40 Cr | 69.00 | 413.85 Cr | 0.1405 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 4.11 Cr | 2,231.84 Cr | 1,134.93 Cr | 1,094.2400 Cr | 796.08 Cr | 791.97 Cr | 317.90 Cr | 1,076.47 Cr | 0.00 Cr | 0.00 Cr | 1.70 Cr | 944.1100 Cr |
| 2024-03-31 | 8.44 Cr | 2,350.96 Cr | 1,414.38 Cr | 933.9100 Cr | 1,011.50 Cr | 1,003.06 Cr | 359.70 Cr | 1,114.22 Cr | 4.19 Cr | 0.00 Cr | 1.70 Cr | 1,242.8500 Cr |
| 2023-03-31 | 8.73 Cr | 2,899.06 Cr | 1,396.60 Cr | 1,500.2200 Cr | 1,012.85 Cr | 1,004.12 Cr | 558.09 Cr | 1,159.05 Cr | 16.01 Cr | -83.31 Cr | 1.70 Cr | 1,100.9000 Cr |
| 2022-03-31 | 46.38 Cr | 2,952.53 Cr | 1,425.35 Cr | 1,524.8700 Cr | 1,037.37 Cr | 990.99 Cr | 575.55 Cr | 1,160.12 Cr | 38.40 Cr | 23.13 Cr | 0.42 Cr | 1,070.9900 Cr |
| 2021-03-31 | 197.69 Cr | 2,613.58 Cr | 1,020.82 Cr | 1,588.5200 Cr | 620.73 Cr | 423.04 Cr | 294.97 Cr | 1,038.86 Cr | 20.29 Cr | 28.49 Cr | 0.42 Cr | 788.7500 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 212.8200 Cr | -36.8300 Cr | -180.4800 Cr | 172.8800 Cr | -4.4900 Cr | 3.9500 Cr | -39.9400 Cr | 0.5400 Cr | -221.3800 Cr | 0.0000 Cr | 41.8000 Cr |
| 2024-03-31 | 108.8700 Cr | -3.5100 Cr | -105.6500 Cr | 67.8100 Cr | -0.2900 Cr | 8.4400 Cr | -41.0600 Cr | -488.4200 Cr | -114.4700 Cr | 0.0000 Cr | 13.0800 Cr |
| 2023-03-31 | 156.2500 Cr | -81.1400 Cr | -112.7600 Cr | 44.9400 Cr | -37.6500 Cr | 8.7300 Cr | -111.3100 Cr | -44.8100 Cr | -64.7500 Cr | 0.0000 Cr | 17.3200 Cr |
| 2022-03-31 | -242.0300 Cr | -242.8500 Cr | 333.5700 Cr | -450.6500 Cr | -151.3100 Cr | 46.3800 Cr | -208.6200 Cr | -91.1000 Cr | 166.1800 Cr | -10.7800 Cr | -280.5800 Cr |
| 2021-03-31 | 155.4600 Cr | -106.3000 Cr | 92.4900 Cr | -19.0200 Cr | 141.6500 Cr | 197.6900 Cr | -174.4800 Cr | 221.5000 Cr | -100.1500 Cr | -19.7300 Cr | -15.2400 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 273.01 Cr | 118.09 Cr | 154.92 Cr | 0.5675 | 102.63 Cr | -2.10 Cr | -0.93 | 45.88 Cr | -0.0077 |
| 2024-12-31 | 300.31 Cr | 134.86 Cr | 165.45 Cr | 0.5509 | 33.14 Cr | 8.09 Cr | 2.03 | 59.17 Cr | 0.0269 |
| 2024-09-30 | 346.95 Cr | 249.94 Cr | 97.01 Cr | 0.2796 | 35.97 Cr | 8.01 Cr | 1.67 | 61.63 Cr | 0.0231 |
| 2024-06-30 | 363.49 Cr | 281.66 Cr | 81.83 Cr | 0.2251 | 16.85 Cr | -13.46 Cr | -3.50 | 42.48 Cr | -0.0370 |
| 2024-03-31 | 262.64 Cr | 159.98 Cr | 102.66 Cr | 0.3909 | -13.79 Cr | -255.34 Cr | -65.37 | -110.72 Cr | -0.9722 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 4.11 Cr | 0.00 Cr | 4.11 Cr | 326.57 Cr | 317.90 Cr | 728.73 Cr | 1,076.47 Cr | 2,231.84 Cr | 1,134.93 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 6.07 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -1,088.69 Cr |
| 2024-09-30 | 5.91 Cr | 12.16 Cr | 18.07 Cr | 0.00 Cr | 289.71 Cr | 759.38 Cr | 1,099.18 Cr | 2,289.78 Cr | 1,201.09 Cr |
| 2024-06-30 | -8.60 Cr | 17.20 Cr | 8.60 Cr | 0.00 Cr | 0.00 Cr | 8.60 Cr | 0.00 Cr | 0.00 Cr | -936.58 Cr |
| 2024-03-31 | 8.32 Cr | 7.58 Cr | 15.90 Cr | 348.52 Cr | 359.70 Cr | 790.65 Cr | 1,107.61 Cr | 2,346.60 Cr | 1,409.18 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | -2.10 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 8.09 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 8.01 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | -13.46 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | -255.34 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2024-05-15 | May 15, 24 | 217:200 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,672.00 | ₹4,011,596,160,000.00 | ₹1,298,300.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,835.00 | ₹1,814,480,615,000.00 | ₹224,031.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,314.20 | ₹1,121,674,419,000.00 | ₹344,196.00 |
| Mankind Pharma Limited | MANKIND | ₹2,578.30 | ₹1,064,138,561,908.00 | ₹2,780,363.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,254.70 | ₹1,044,010,449,778.00 | ₹895,308.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹979.60 | ₹985,702,908,000.00 | ₹921,030.00 |
| Lupin Limited | LUPIN | ₹1,894.70 | ₹865,339,805,200.00 | ₹1,511,045.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,124.80 | ₹653,286,089,600.00 | ₹1,058,782.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,181.10 | ₹615,508,601,100.00 | ₹15,678,334.00 |
| Alkem Laboratories Limited | ALKEM | ₹4,806.70 | ₹574,713,085,500.00 | ₹183,070.00 |
| Laurus Labs Limited | LAURUSLABS | ₹790.20 | ₹426,117,720,600.00 | ₹1,475,669.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Cohance Lifesciences Limited | COHANCE | ₹1,017.95 | ₹389,434,085,794.00 | ₹322,114.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,449.60 | ₹367,769,318,400.00 | ₹119,065.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,626.50 | ₹328,081,368,000.00 | ₹236,895.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,757.10 | ₹285,491,850,900.00 | ₹3,159,181.00 |
| Piramal Enterprises Limited | PEL | ₹1,217.50 | ₹275,980,465,000.00 | ₹2,508,249.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,608.60 | ₹251,036,507,400.00 | ₹444,444.00 |
| Eris Lifesciences Limited | ERIS | ₹1,709.80 | ₹232,869,630,600.00 | ₹106,770.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,241.50 | ₹231,037,500,000.00 | ₹20,847.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹976.60 | ₹191,963,425,800.00 | ₹60,016.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,165.70 | ₹185,673,861,700.00 | ₹144,076.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹961.80 | ₹172,267,998,000.00 | ₹1,353,979.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹12,301.00 | ₹157,820,599,900.00 | ₹74,663.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,023.30 | ₹153,794,472,610.00 | ₹35,929.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹469.00 | ₹113,800,036,000.00 | ₹331,193.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,755.50 | ₹95,537,846,700.00 | ₹23,112.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹896.75 | ₹87,693,989,575.00 | ₹154,034.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹927.20 | ₹84,036,419,664.00 | ₹291,915.00 |
| Strides Pharma Science Limited | STAR | ₹887.80 | ₹81,822,045,060.00 | ₹428,094.00 |
| FDC Limited | FDC | ₹501.35 | ₹81,624,793,500.00 | ₹72,209.00 |
| Suven Life Sciences Limited | SUVEN | ₹276.63 | ₹60,325,810,620.00 | ₹285,602.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹159.34 | ₹51,709,335,480.00 | ₹1,252,722.00 |
| Innova Captab Limited | INNOVACAP | ₹875.40 | ₹50,094,703,722.00 | ₹46,543.00 |
| Sequent Scientific Limited | SEQUENT | ₹184.32 | ₹46,136,217,600.00 | ₹343,582.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹473.60 | ₹43,225,472,000.00 | ₹158,284.00 |
| Hikal Limited | HIKAL | ₹340.50 | ₹41,983,990,500.00 | ₹164,468.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,526.20 | ₹41,780,821,800.00 | ₹17,230.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹590.85 | ₹41,599,266,930.00 | ₹17,355.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹718.30 | ₹36,431,529,530.00 | ₹55,088.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹349.05 | ₹35,002,035,900.00 | ₹50,065.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹62.67 | ₹34,340,277,180.00 | ₹1,978,828.00 |
| Solara Active Pharma Sciences Limited | SOLARA | ₹664.85 | ₹32,014,522,050.00 | ₹589,436.00 |
| Indoco Remedies Limited | INDOCO | ₹326.45 | ₹30,114,326,955.00 | ₹174,646.00 |
| Alembic Limited | ALEMBICLTD | ₹117.26 | ₹30,110,257,203.00 | ₹332,328.00 |
| IOL Chemicals and Pharmaceuticals Limited | IOLCP | ₹91.18 | ₹26,763,791,860.00 | ₹1,225,212.00 |
Key Executives
Chief Executive Officer & MD
Mr. Sandeep Rao M.Sc., PGDM
Gender: male
Year Born: 1973
Chief Commercial Officer
Mr. Vishal Mathur
Gender: male
Year Born:
Chief Financial Officer
Mr. Sarat Kumar
Gender: male
Year Born:
Chief Operating Officer & Executive Director
Mr. Mohan Muthunarayanan
Gender: male
Year Born:
Company Secretary, Compliance Officer & Chief Investor Relations Officer
Mr. Suddapalli Murali Krishna
Gender: male
Year Born:
Chief Quality Officer
Mr. V. Sundara Moorthy
Gender: male
Year Born:
Founder & Non-Executive Director
Mr. Arun Kumar Pillai B.Com.
Gender: male
Year Born: 1961
Chief Scientific Officer
Dr. Hero Velladurai
Gender: Not Specified
Year Born:
FAQs about Solara Active Pharma Sciences Limited
Who is the CEO of the company?
The CEO is Sandeep Rao PGDM.
What is the current market price of the stock?
The current price is ₹664.85.
What is the 52-week price range?
The range is ₹442.8-882.8.
What is the market capitalization of the company?
The market capitalization is ₹3,201.45 crores.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 2,780.18.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Solara Active Pharma Sciences Limited (ISIN: INE624Z01016) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹3,201.45 crores and an average daily volume of 215,459 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.